Buchumschlag

Antibody-based and cell therapies for advanced mastocytosis: established and novel concepts

Advanced systemic mastocytosis (SM) is a heterogeneous group of myeloid neoplasms characterized by an uncontrolled expansion of mast cells (MC) in one or more internal organs, SM-induced tissue damage, and poor prognosis. Advanced SM can be categorized into aggressive SM (ASM), MC leukemia (MCL), an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Valent, Peter (VerfasserIn) , Akin, Cem (VerfasserIn) , Arock, Michel (VerfasserIn) , Gleixner, Karoline V. (VerfasserIn) , Greinix, Hildegard (VerfasserIn) , Hermine, Olivier (VerfasserIn) , Horny, Hans-Peter (VerfasserIn) , Ivanov, Daniel (VerfasserIn) , Orfao, Alberto (VerfasserIn) , Rabitsch, Werner (VerfasserIn) , Reiter, Andreas (VerfasserIn) , Schulenburg, Axel (VerfasserIn) , Sotlar, Karl (VerfasserIn) , Sperr, Wolfgang Reinhard (VerfasserIn) , Ustun, Celalettin (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 12 October 2023
In: International journal of molecular sciences
Year: 2023, Jahrgang: 24, Heft: 20, Pages: 1-14
ISSN:1422-0067
DOI:10.3390/ijms242015125
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/ijms242015125
Verlag, kostenfrei, Volltext: https://www.mdpi.com/1422-0067/24/20/15125
Volltext
Verfasserangaben:Peter Valent, Cem Akin, Michel Arock, Karoline V. Gleixner, Hildegard Greinix, Olivier Hermine, Hans-Peter Horny, Daniel Ivanov, Alberto Orfao, Werner Rabitsch, Andreas Reiter, Axel Schulenburg, Karl Sotlar, Wolfgang R. Sperr and Celalettin Ustun
Beschreibung
Zusammenfassung:Advanced systemic mastocytosis (SM) is a heterogeneous group of myeloid neoplasms characterized by an uncontrolled expansion of mast cells (MC) in one or more internal organs, SM-induced tissue damage, and poor prognosis. Advanced SM can be categorized into aggressive SM (ASM), MC leukemia (MCL), and SM with an associated hematologic neoplasm (SM-AHN). In a vast majority of all patients, neoplastic cells display a KIT mutation, mostly D816V and rarely other KIT variants. Additional mutations in other target genes, such as SRSF2, ASXL1, or RUNX1, may also be identified, especially when an AHN is present. During the past 10 years, improved treatment approaches have led to a better quality of life and survival in patients with advanced SM. However, despite the availability of novel potent inhibitors of KIT D816V, not all patients enter remission and others relapse, often with a multi-mutated and sometimes KIT D816V-negative disease exhibiting multi-drug resistance. For these patients, (poly)chemotherapy, antibody-based therapies, and allogeneic hematopoietic stem cell transplantation may be viable treatment alternatives. In this article, we discuss treatment options for patients with drug-resistant advanced SM, including novel KIT-targeting drugs, antibody-based drugs, and stem cell-eradicating therapies.
Beschreibung:Gesehen am 19.03.2024
Beschreibung:Online Resource
ISSN:1422-0067
DOI:10.3390/ijms242015125

Ähnliche Einträge